| 2023-08-15 | +75.3% | legal | SEC EDGAR | DCTH 8-K: 7.01, 8.01 (SEC Filing) |
| 2023-08-15 | +75.3% | legal | Dhaka Tribune | Delcath Systems (NASDAQ: DCTH) stock up 66% premarket on FDA approval - Dhaka Tribune |
| 2024-05-14 | +31.4% | legal | SEC EDGAR | DCTH 8-K: 2.02 and (SEC Filing) |
| 2024-05-14 | +31.4% | news | Stock Titan | Delcath Systems Reports First Quarter 2024 Results and Business Highlights - Stock Titan |
| 2025-05-08 | +27.3% | earnings | Seeking Alpha | Delcath Systems, Inc. 2025 Q1 - Results - Earnings Call Presentation |
| 2025-05-08 | +27.3% | earnings | Seeking Alpha | Delcath Systems targets 30 active centers by year-end 2025 amid strong Q1 performance |
| 2025-05-08 | +27.3% | earnings | Seeking Alpha | Delcath Systems, Inc. (DCTH) Q1 2025 Earnings Call Transcript |
| 2025-05-08 | +27.3% | earnings | Seeking Alpha | Delcath Systems GAAP EPS of $0.03 beats by $0.02, revenue of $19.78M beats by $2.95M |
| 2025-05-08 | +27.3% | legal | SEC EDGAR | DCTH 8-K: 2.02 (SEC Filing) |
| 2025-05-08 | +27.3% | news | Yahoo Finance | Delcath Systems Reports First Quarter 2025 Results and Business Highlights - Yahoo Finance |
| 2023-11-13 | -25.6% | legal | SEC EDGAR | DCTH 8-K: 2.02 and (SEC Filing) |
| 2023-03-27 | +22.4% | legal | SEC EDGAR | DCTH 8-K: 2.02 and (SEC Filing) |
| 2025-05-07 | +21.4% | earnings | Seeking Alpha | Delcath Systems Q1 2025 Earnings Preview |
| 2023-08-09 | -20.0% | legal | SEC EDGAR | DCTH 8-K: 2.02 and (SEC Filing) |
| 2021-12-02 | -19.2% | legal | SEC EDGAR | DCTH 8-K: 7.01, 8.01 (SEC Filing) |
| 2024-10-17 | +18.2% | legal | SEC EDGAR | DCTH 8-K: 2.02, 8.01 (SEC Filing) |
| 2024-04-19 | +17.3% | analyst | eToro | DCTH Stock Price | Analyst Target 28.50 & Consensus - eToro |
| 2025-05-16 | +12.0% | legal | SEC EDGAR | DCTH 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-02-26 | -11.8% | earnings | GuruFocus.com | Delcath Systems Inc (DCTH) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ... |
| 2026-02-26 | -11.8% | earnings | MarketBeat | Delcath Systems Q4 Earnings Call Highlights |
| 2026-02-26 | -11.8% | earnings | Motley Fool | Delcath (DCTH) Q4 2025 Earnings Call Transcript |
| 2026-02-26 | -11.8% | earnings | Moby | Delcath Systems, Inc. Q4 2025 Earnings Call Summary |
| 2026-02-26 | -11.8% | earnings | Seeking Alpha | Delcath targets at least $100M revenue in 2026 while expanding to 40 treatment centers |
| 2026-02-26 | -11.8% | earnings | Seeking Alpha | Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript |
| 2026-02-26 | -11.8% | earnings | Seeking Alpha | Delcath Systems GAAP EPS of -$0.05 misses by $0.01, revenue of $20.73M beats by $0.05M |
| 2026-02-26 | -11.8% | legal | SEC EDGAR | DCTH 8-K: 2.02 (SEC Filing) |
| 2026-02-26 | -11.8% | earnings | ChartMill | Delcath Systems Inc (NASDAQ:DCTH) Posts Q4 Beat, Provides Cautious 2026 Outlook - ChartMill |
| 2024-07-19 | +11.6% | legal | SEC EDGAR | DCTH 8-K: 5.02 and (SEC Filing) |
| 2022-07-20 | +11.2% | legal | SEC EDGAR | DCTH 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2025-01-13 | +10.2% | legal | SEC EDGAR | DCTH 8-K: 2.02, 7.01, 8.01 (SEC Filing) |
| 2025-11-21 | +10.2% | news | simplywall.st | Why We're Not Concerned Yet About Delcath Systems, Inc.'s (NASDAQ:DCTH) 28% Share Price Plunge - simplywall.st |
| 2026-02-25 | -9.8% | earnings | Seeking Alpha | Delcath Systems Q4 2025 Earnings Preview |
| 2022-05-11 | -9.6% | legal | SEC EDGAR | DCTH 8-K: 2.02 and (SEC Filing) |
| 2024-11-08 | -9.5% | legal | SEC EDGAR | DCTH 8-K: 2.02 and (SEC Filing) |
| 2021-06-29 | +9.2% | legal | SEC EDGAR | DCTH 8-K: 3.02 (SEC Filing) |
| 2024-03-26 | +8.6% | legal | SEC EDGAR | DCTH 8-K: 2.02 and (SEC Filing) |
| 2024-03-26 | +8.6% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2023-06-13 | -8.5% | legal | SEC EDGAR | DCTH 8-K: 5.02, 5.03, 5.07 (SEC Filing) |
| 2025-11-04 | -8.0% | news | Seeking Alpha | Delcath outlines 40 active center target and 150% HEPZATO treatment volume growth for 2025 amid CHOPIN data momentum |
| 2025-11-04 | -8.0% | earnings | Seeking Alpha | Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript |
| 2025-11-04 | -8.0% | earnings | Seeking Alpha | Delcath Systems GAAP EPS of $0.02 beats by $0.08, revenue of $20.56M |
| 2025-11-04 | -8.0% | legal | SEC EDGAR | DCTH 8-K: 2.02 (SEC Filing) |
| 2022-06-07 | -7.6% | legal | SEC EDGAR | DCTH 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-12-03 | +7.2% | news | Yahoo Finance | Investors in Delcath Systems (NASDAQ:DCTH) have seen splendid returns of 221% over the past three years - Yahoo Finance |
| 2024-05-29 | -6.7% | legal | SEC EDGAR | DCTH 8-K: 3.01, 5.02, 5.07 (SEC Filing) |
| 2024-01-31 | +6.7% | legal | SEC EDGAR | DCTH 8-K: 8.01 and (SEC Filing) |
| 2025-11-03 | -6.6% | earnings | Seeking Alpha | Delcath Systems Q3 2025 Earnings Preview |
| 2025-09-04 | +6.3% | news | Yahoo Finance | Invesco Backs Delcath Systems (DCTH) on Expansion Potential - Yahoo Finance |
| 2023-05-23 | +6.2% | analyst | TradingView | DCTH Forecast — Price Target — Prediction for 2027 - TradingView |
| 2026-04-13 | +6.2% | news | Cổng thông tin điện tử tỉnh Lào Cai | Is Delcath (DCTH) Stock Discounted Now | Price at $10.18, Up 1.34% - Bearish Pattern - Cổng thông tin điện tử tỉnh Lào Cai |
| 2025-10-20 | -5.9% | earnings | Seeking Alpha | Delcath Systems, Inc. (DCTH) Discusses CHOPIN Trial Results and Preliminary Q3 Financials Transcript |
| 2025-10-20 | -5.9% | news | Seeking Alpha | Delcath: Large Upside With Limited Downside Risk |
| 2025-10-20 | -5.9% | earnings | Seeking Alpha | Delcath Systems reports $20.5M Q3 revenue, lowers FY revenue guidance |
| 2025-10-20 | -5.9% | legal | SEC EDGAR | DCTH 8-K: 2.02, 7.01, 8.01 (SEC Filing) |
| 2025-10-20 | -5.9% | news | Seeking Alpha | Delcath: Large Upside With Limited Downside Risk (NASDAQ:DCTH) - Seeking Alpha |
| 2025-10-20 | -5.9% | news | Benzinga | Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket - Benzinga |
| 2025-10-20 | -5.9% | news | TipRanks | Delcath Systems Reports Positive CHOPIN Trial Results - TipRanks |
| 2025-05-22 | -5.9% | expansion | Seeking Alpha | Delcath sets outlook amid plans to enter National Medicaid Drug Rebate Agreement |
| 2025-05-22 | -5.9% | legal | SEC EDGAR | DCTH 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-08-05 | -5.8% | earnings | Seeking Alpha | Delcath Systems Q2 2025 Earnings Preview |
| 2025-11-20 | +5.8% | news | Seeking Alpha | Delcath Systems authorizes $25 million share repurchase program |
| 2025-11-20 | +5.8% | legal | SEC EDGAR | DCTH 8-K: 8.01 (SEC Filing) |
| 2021-07-17 | -5.8% | earnings | Zacks Investment Research | What date does Delcath Systems's (DCTH) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2021-10-26 | +5.8% | legal | SEC EDGAR | DCTH 8-K: 5.02 (SEC Filing) |
| 2025-05-18 | +5.7% | earnings | Seeking Alpha | Delcath Systems: Q1 Earnings Show A Growth Spurt And Switch To Execution |
| 2026-03-04 | +5.4% | news | TipRanks | Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology |
| 2025-08-09 | +5.2% | earnings | simplywall.st | Delcath Systems, Inc. Just Recorded A 200% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st |
| 2021-08-11 | -5.1% | legal | SEC EDGAR | DCTH 8-K: 1.01, 2.02, 2.03, 3.02, 8.01 (SEC Filing) |
| 2025-06-18 | -4.8% | news | simplywall.st | Delcath Systems (NASDAQ:DCTH) Is In A Strong Position To Grow Its Business - simplywall.st |
| 2025-04-03 | -4.7% | news | Seeking Alpha | Stryker, Boston Scientific down as new tariffs impact medtech industry |
| 2021-11-10 | -4.5% | legal | SEC EDGAR | DCTH 8-K: 2.02 and (SEC Filing) |
| 2026-01-23 | -4.5% | news | DirectorsTalk Interviews | Delcath Systems, Inc. (DCTH) Stock Analysis: A 103% Upside Potential In Medical Devices - DirectorsTalk Interviews |
| 2025-08-12 | +4.3% | news | Seeking Alpha | Delcath Systems: Huge Potential But With The Handbrake On For Now |
| 2025-08-12 | +4.3% | news | Seeking Alpha | Delcath Systems: Huge Potential But With The Handbrake On For Now (NASDAQ:DCTH) - Seeking Alpha |
| 2025-11-05 | -4.1% | news | BioSpace | Delcath Systems Reports Third Quarter 2025 Results and Business Highlights - BioSpace |
| 2025-11-05 | -4.1% | analyst | GuruFocus | Delcath Systems (DCTH) Analyst Rating Update: Price Target Lowered to $18 | DCTH Stock News - GuruFocus |
| 2025-06-24 | +4.0% | news | Yahoo Finance | Loss-Making Delcath Systems, Inc. (NASDAQ:DCTH) Set To Breakeven - Yahoo Finance |
| 2025-08-06 | -3.8% | news | Seeking Alpha | Delcath outlines 175% projected HEPZATO volume growth and targets up to 28 operational centers by year-end 2025 amid expanding clinical pipeline |
| 2025-08-06 | -3.8% | earnings | Seeking Alpha | Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript |
| 2025-08-06 | -3.8% | earnings | Seeking Alpha | Delcath Systems GAAP EPS of $0.07 beats by $0.05, revenue of $24.2M beats by $1.18M |
| 2025-08-06 | -3.8% | legal | SEC EDGAR | DCTH 8-K: 2.02 (SEC Filing) |
| 2025-07-29 | -3.8% | legal | Stock Titan | Delcath Systems Secures Spot at Elite Canaccord Growth Conference, Key Investor Presentation Coming - Stock Titan |
| 2026-03-03 | +3.5% | news | Business Wire | Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology |
| 2026-03-03 | +3.5% | legal | SEC EDGAR | DCTH 8-K: 8.01 and (SEC Filing) |
| 2026-03-03 | +3.5% | news | Stock Titan | Liver-directed therapy plus immunotherapy extends survival in uveal melanoma - Stock Titan |
| 2026-03-03 | +3.5% | news | Stock Titan | CHOPIN uveal melanoma trial data in Lancet boosts Delcath (Nasdaq: DCTH) - Stock Titan |
| 2026-04-23 | -3.5% | earnings | Business Wire | Delcath Systems to Host First Quarter 2026 Earnings Call |
| 2026-04-23 | -3.5% | earnings | Stock Titan | Delcath Systems will discuss Q1 results on a May 7 morning call - Stock Titan |
| 2025-06-12 | -3.2% | news | Seeking Alpha | Delcath Systems: Growing Fast, But Business Model Is Fragile |
| 2025-06-12 | -3.2% | news | Seeking Alpha | Delcath Systems: Growing Fast, But Business Model Is Fragile (NASDAQ:DCTH) - Seeking Alpha |
| 2026-04-11 | +3.1% | legal | Stock Titan | DCTH SEC Filings - Delcath Sys 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2025-10-28 | -3.0% | analyst | Yahoo Finance | Time To Worry? Analysts Just Downgraded Their Delcath Systems, Inc. (NASDAQ:DCTH) Outlook - Yahoo Finance |
| 2026-04-01 | +2.9% | news | Business Wire | Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting |
| 2026-04-01 | +2.9% | news | Stock Titan | Three doctors to present Delcath liver cancer therapy data at SIR 2026 - Stock Titan |
| 2024-08-28 | +2.8% | legal | SEC EDGAR | DCTH 8-K: 8.01 and (SEC Filing) |
| 2023-02-14 | -2.7% | legal | SEC EDGAR | DCTH 8-K: 8.01 and (SEC Filing) |
| 2024-02-14 | -2.7% | legal | SEC EDGAR | DCTH 8-K: 5.02 (SEC Filing) |
| 2025-10-23 | -2.7% | news | Yahoo Finance | Delcath Systems (DCTH): Assessing Valuation Following Promising CHOPIN Trial Results and Updated Growth Outlook - Yahoo Finance |
| 2026-03-02 | -2.5% | news | Seeking Alpha | Delcath: Fundamentals Intact, Despite Share Price Weakness |
| 2026-03-02 | -2.5% | news | Seeking Alpha | Delcath: Fundamentals Intact, Despite Share Price Weakness (NASDAQ:DCTH) - Seeking Alpha |
| 2026-02-20 | +2.5% | legal | DirectorsTalk Interviews | Delcath Systems, Inc. (DCTH) Stock Analysis: Exploring a Potential 134% Upside in the Healthcare Sector - DirectorsTalk Interviews |
| 2026-04-21 | +2.5% | earnings | MarketBeat | Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat |
| 2024-04-26 | -2.3% | legal | SEC EDGAR | DCTH 8-K: 1.01 (SEC Filing) |
| 2025-02-07 | -2.2% | news | Seeking Alpha | Delcath Systems: Strong Position In Metastatic Uveal Melanoma, But Broader Growth Challenges Ahead - Seeking Alpha |
| 2024-12-30 | +2.2% | legal | SEC EDGAR | DCTH 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-03-06 | -2.0% | legal | SEC EDGAR | DCTH 8-K: 2.02 and (SEC Filing) |
| 2026-03-20 | -1.9% | news | Stock Titan | Daniel Kaufman reports 5.08% stake in Delcath Systems (DCTH) - Stock Titan |
| 2023-03-30 | +1.8% | legal | SEC EDGAR | DCTH 8-K: 1.01, 3.02, 5.03, 8.01 (SEC Filing) |
| 2023-01-10 | -1.7% | legal | SEC EDGAR | DCTH 8-K: 8.01 (SEC Filing) |
| 2023-02-18 | +1.6% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Delcath Systems (DCTH) - Zacks Investment Research |
| 2023-01-23 | +1.6% | legal | SEC EDGAR | DCTH 8-K: 8.01 (SEC Filing) |
| 2026-01-13 | +1.6% | analyst | Seeking Alpha | Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade |
| 2026-01-13 | +1.6% | analyst | Seeking Alpha | Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade (NASDAQ:DCTH) - Seeking Alpha |
| 2026-04-07 | -1.0% | news | Zacks | Implied Volatility Surging for Delcath Systems Stock Options |
| 2026-04-07 | -1.0% | news | TradingView | Implied Volatility Surging for Delcath Systems Stock Options - TradingView |
| 2026-04-07 | -1.0% | news | MSN | Implied volatility surging for Delcath Systems stock options - MSN |
| 2023-06-07 | -1.0% | legal | SEC EDGAR | DCTH 8-K: 5.02, 7.01 (SEC Filing) |
| 2022-03-29 | +1.0% | legal | SEC EDGAR | DCTH 8-K: 2.02 and (SEC Filing) |
| 2023-06-22 | +0.9% | legal | SEC EDGAR | DCTH 8-K: 8.01 and (SEC Filing) |
| 2026-01-12 | +0.8% | legal | SEC EDGAR | DCTH 8-K: 2.02, 7.01, 8.01 (SEC Filing) |
| 2023-02-24 | -0.7% | legal | SEC EDGAR | DCTH 8-K: 8.01 (SEC Filing) |
| 2021-05-12 | -0.7% | legal | SEC EDGAR | DCTH 8-K: 2.02 and (SEC Filing) |
| 2024-08-05 | -0.6% | legal | SEC EDGAR | DCTH 8-K: 2.02 and (SEC Filing) |
| 2024-12-29 | +0.6% | analyst | Yahoo Finance | Analysts Expect Breakeven For Delcath Systems, Inc. (NASDAQ:DCTH) Before Long - Yahoo Finance |
| 2026-04-17 | -0.5% | news | Cổng thông tin điện tử Tỉnh Sơn La | Delcath (DCTH) Stock Adds to Position (-1.46%) 2026-04-16 - Asset Allocation - Cổng thông tin điện tử Tỉnh Sơn La |
| 2025-11-06 | +0.5% | news | Seeking Alpha | Delcath: Temporary Headwinds Are No Cause For Concern |
| 2025-11-06 | +0.5% | news | Seeking Alpha | Delcath: Temporary Headwinds Are No Cause For Concern (NASDAQ:DCTH) - Seeking Alpha |
| 2026-04-19 | +0.4% | earnings | MarketBeat | JPMorgan Chase & Co. Decreases Position in Delcath Systems, Inc. $DCTH - MarketBeat |
| 2026-04-18 | +0.4% | earnings | MarketBeat | Delcath Systems (NASDAQ:DCTH) Stock Price Up 0.3% - Time to Buy? - MarketBeat |
| 2024-03-19 | +0.2% | legal | SEC EDGAR | DCTH 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2024-03-19 | +0.2% | legal | SEC EDGAR | DCTH 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-06 | -0.1% | news | Business Wire | Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma |
| 2026-04-06 | -0.1% | news | Stock Titan | European cancer guidelines add Delcath liver therapy for eye melanoma - Stock Titan |
| 2026-04-06 | -0.1% | news | Cổng thông tin điện tử tỉnh Lào Cai | Is Delcath (DCTH) Stock Safe to Buy Now | Price at $9.76, Up 1.35% - Stock Ideas - Cổng thông tin điện tử tỉnh Lào Cai |
| 2025-04-28 | +0.1% | legal | GuruFocus | Delcath Systems (DCTH) Cleared by FDA to Start Phase 2 Trial for Hepzato | DCTH Stock News - GuruFocus |
| 2023-05-12 | -0.0% | legal | SEC EDGAR | DCTH 8-K: 2.02 and (SEC Filing) |
| 2026-01-09 | -0.0% | earnings | Seeking Alpha | Delcath Systems expects FY revenue of $85.2 million |
| 2022-12-13 | +0.0% | legal | SEC EDGAR | DCTH 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2026-04-25 | — | news | Stock Traders Daily | How Delcath Systems Inc. (DCTH) Affects Rotational Strategy Timing - Stock Traders Daily |